It's How Medicine Should Be®
<< Previous | New Search | Return to Search Results | Next >>

Physician Profile


call (888) 352-RUSH for help arranging an appointment

Dusan Stefoski, MD

Patient Feedback
  • Neurology
Board Certification:
  • Neurology
Faculty Rank: Associate Professor
Medical or Graduate Education: University of Zagreb School of Medicine, Croatia
Residency: Rush University Medical Center - Neurology
Fellowship: Rush University Medical Center - Multiple Sclerosis
Clinical Expertise:
  • Ataxia
  • Botulinum toxin injections
  • Lumbar puncture
  • Multiple sclerosis
  • Optic neuritis
  • Transcranial magnetic stimulation
Research Interests:
  • Multiple sclerosis
Languages Spoken:
  • Croatian
  • German
  • Serbian
Google Map

Below is a list of scientific publications for which this practitioner was either the primary author or a contributor. Citations come from PubMed, a database of biomedical literature, life science journals and online books. PubMed is a service of the US Library of Medicine at the National Institutes of Health. Click on the title of the cited work for more information (this will take you directly to Listings go back five years.

  1. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial.
    Giovannoni G, Gold R, Selmaj K, Havrdova E, Montalban X, Radue EW, Stefoski D, McNeill M, Amaravadi L, Sweetser M, Elkins J, O'Neill G,
    Lancet Neurol
    2014 May
  2. Autoimmune Aquaporin-4 Myopathy in Neuromyelitis Optica Spectrum.
    Guo Y, Lennon VA, Popescu BF, Grouse CK, Topel J, Milone M, Lassmann H, Parisi JE, Pittock SJ, Stefoski D, Balabanov R, Lucchinetti CF
    JAMA Neurol
    2014 Jun 9
  3. Is cervical decompression beneficial in patients with coexistent cervical stenosis and multiple sclerosis?
    Tan LA, Kasliwal MK, Muth CC, Stefoski D, Traynelis VC
    J Clin Neurosci
    2014 Jul 31
  4. Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study.
    Havrdova E, Giovannoni G, Stefoski D, Forster S, Umans K, Mehta L, Greenberg S, Elkins J
    Mult. Scler.
    2013 Sep 10
  5. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial.
    Gold R, Giovannoni G, Selmaj K, Havrdova E, Montalban X, Radue EW, Stefoski D, Robinson R, Riester K, Rana J, Elkins J, O'Neill G; for the SELECT study investigators.
    Lancet. 2013
    2013 Apr 3. doi:pii: S0140-6736(12)62190-4. 10.1016/S0140-6736(12)62190-4. [Epub ahead of print]
  6. Cross-immunoreactivity between bacterial aquaporin-Z and human aquaporin-4: potential relevance to neuromyelitis optica.
    Ren Z, Wang Y, Duan T, Patel J, Liggett T, Loda E, Brahma S, Goswami R, Grouse C, Byrne R, Stefoski D, Javed A, Miller SD, Balabanov R.
    J Immunol. 2012
    2012 Nov 1
    189(9):4602-11. doi: 10.4049/jimmunol.1200486. Epub 2012 Sep 24.
  7. Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS.
    Ko MY, Stefoski D, Balabanov R.
    Neurology. 2011
    2011 Sep 6
    77(10):1020; author reply 1020. doi: 10.1212/WNL.0b013e31822946d0. No abstract available.
  8. Overexpression of the dominant-negative form of interferon regulatory factor 1 in oligodendrocytes protects against experimental autoimmune encephalomyelitis.
    Ren Z, Wang Y, Tao D, Liebenson D, Liggett T, Goswami R, Clarke R, Stefoski D, Balabanov R.
    J Neurosci. 2011
    2011 Jun 8
    31(23):8329-41. doi: 10.1523/JNEUROSCI.1028-11.2011.
  9. IRF-1 signaling in central nervous system glial cells regulates inflammatory demyelination.
    Ren Z, Wang Y, Liebenson D, Liggett T, Goswami R, Stefoski D, Balabanov R.
    J Neuroimmunol. 2011
    2011 Apr
    233(1-2):147-59. doi: 10.1016/j.jneuroim.2011.01.001. Epub 2011 Jan 22.
  10. Methylation patterns of cell-free plasma DNA in relapsing-remitting multiple sclerosis.
    Liggett T, Melnikov A, Tilwalli S, Yi Q, Chen H, Replogle C, Feng X, Reder A, Stefoski D, Balabanov R, Levenson V.
    J Neurol Sci. 2010
    2010 Mar 15
    290(1-2):16-21. doi: 10.1016/j.jns.2009.12.018. Epub 2010 Jan 12.
  11. Central nervous system expression of interferon regulatory factor 1 regulates experimental autoimmune encephalomyelitis.
    Ren Z, Wang Y, Tao D, Liebenson D, Liggett T, Goswami R, Stefoski D, Balabanov R.
    J Neuroimmune Pharmacol. 2010
    2010 Jun
    5(2):260-5. doi: 10.1007/s11481-010-9193-z. Epub 2010 Feb 23.
  12. Freedom from disease activity in multiple sclerosis.
    Havrdova E, Galetta S, Stefoski D, Comi G.
    Neurology. 2010
    2010 Apr 27
    74 Suppl 3:S3-7. doi: 10.1212/WNL.0b013e3181dbb51c.
  13. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study.
    Havrdova E, Galetta S, Hutchinson M, Stefoski D, Bates D, Polman CH, O'Connor PW, Giovannoni G, Phillips JT, Lublin FD, Pace A, Kim R, Hyde R.
    Lancet Neurol. 2009
    2009 Mar
    8(3):254-60. doi: 10.1016/S1474-4422(09)70021-3. Epub 2009 Feb 7.
  14. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study.
    Burt RK, Loh Y, Cohen B, Stefoski D, Balabanov R, Katsamakis G, Oyama Y, Russell EJ, Stern J, Muraro P, Rose J, Testori A, Bucha J, Jovanovic B, Milanetti F, Storek J, Voltarelli JC, Burns WH.
    Lancet Neurol. 2009
    2009 Mar
    8(3):244-53. doi: 10.1016/S1474-4422(09)70017-1. Epub 2009 Jan 29. Erratum in: Lancet Neurol. 2009 Apr;8(4):309. Stefosky, Dusan [corrected to Stefoski, Dusan].
  15. A pilot test of pioglitazone as an add-on in patients with relapsing remitting multiple sclerosis.
    Kaiser CC, Shukla DK, Stebbins GT, Skias DD, Jeffery DR, Stefoski D, Katsamakis G, Feinstein DL.
    J Neuroimmunol. 2009
    2009 Jun 25
    211(1-2):124-30. doi: 10.1016/j.jneuroim.2009.04.011. Epub 2009 May 15.
Patient feedback information is available for physicians employed by Rush University Medical Center who have received 30 or more patient surveys. Responses are measured on a scale of 1 to 5, with 5 being the best score.
Number of Patient Surveys
Friendliness/courtesy of the care provider
Explanations the care provider gave you about your problem or condition
Concern the care provider showed for your questions or worries
Likelihood of your recommending this care provider to others
Care provider's efforts to include you in decisions about your treatment
Information the care provider gave you about medications
Instructions the care provider gave you about follow-up care
Your confidence in this care provider
Degree to which care provider talked with you using words you could understand
Amount of time the care provider spent with you
For more information about patient feedback, see the Quality Care section of the Rush University Medical Center website.